A prospective study of dextran-induced anaphylactoid reactions (DIAR) in 5745
gynaecological and obstetric patients who received dextran 70 solution intravenously while …

From 1968 to 1975, the Swedish Adverse Drug Reaction Committee received 113 reports on
anaphylactoid reaction to dextran 70, and 20 reports on the same reaction to dextran 40. For …

Dextran is used clinically for plasma volume expansion, improvement of blood flow and
thromboprophylaxis, but has been associated with untoward side effects …

The incidence of dextran-induced anaphylactoid/anaphylactic reactions (DIAR) was
investigated after hapten inhibition employing two different modes of administration of …

Two of four new cases of anaphylactoid reactions associated with the use of dextran 70
occurred in a consecutive series of 84 hemodynamically stable patients, an incidence of …

In a retrospective investigation of the period 1970-1979, 478 reports on cases of dextran-
induced anaphylactoid/anaphylactic reactions (DIAR) were found. In 458 of these dextran …

Dextran-60 is widely used as a colloid volume substitute and for thromboprophylaxis. In
order to avoid the most dangerous complication associated with dextran, the dextran …

Prevention of deep vein thrombosis, thromboembolism, and fatal pulmonary embolism is a
major consideration in the perioperative period. Dextran, a polysaccharide with an average …

In an open prospective study the prevention of dextran-induced anaphylactic reactions
(DIAR) by hapten inhibition was investigated in 29 252 patients. Forty-nine hospitals in …

In an open, prospective multi-center study prevention of dextran-induced anaphylactic
reactions (DIAR) was attempted by intravenous injection of 20 ml dextran 1, 15%, Mw 1000 …